Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Long-Term Ravulizumab Efficacy and Safety in AQP4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: Final CHAMPION-NMOSD Results.

Neurology(R) neuroimmunology & neuroinflammation·2026
Same author

Profiling the long-term risk of severe adverse events in a cohort of multiple sclerosis patients treated with different treatment sequences: Results from the Italian Multiple Sclerosis and Related Disorders Registry (I-MS&RD) (ProSA study).

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Targeting shared immune pathways in multiple sclerosis and type 1 diabetes: Therapeutic insights from monoclonal antibodies.

Autoimmunity reviews·2026
Same author

A predictive tool for early treatment escalation after initiation of moderate-efficacy therapy in pediatric-onset multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Use of High-Efficacy Therapy in Children With Multiple Sclerosis to Prevent Long-Term Disability.

Neurology·2026
Same author

Reduced Childhood Outdoor Exposure Raises Pediatric Multiple Sclerosis (PedMS) Risk.

Neurology and therapy·2026

相关实验视频

Updated: May 12, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.0K

多发性硬化症在儿童中的进展和复发活动

Pietro Iaffaldano1, Emilio Portaccio2, Giuseppe Lucisano1,3

  • 1Department of Translational Biomedicines and Neurosciences, University of Bari Aldo Moro, Bari, Italy.

JAMA neurology
|November 27, 2023
PubMed
概括

与成人相比,儿科发病多发性硬化症 (MS) 患者的不依赖复发性活性 (PIRA) 的进展率较低. 在所有多发性硬化患者中,早期启动疾病修饰疗法 (DMT) 对于减少PIRA和复发相关恶化 (RAW) 至关重要.

更多相关视频

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.7K
Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

858

相关实验视频

Last Updated: May 12, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.0K
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.7K
Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

858

科学领域:

  • 神经学 神经学
  • 免疫学 免疫学 免疫学
  • 临床研究 临床研究

背景情况:

  • 儿科发病多发性硬化症 (POMS) 占MS病例的20%,具有更大的修复能力的潜力.
  • 以前的假设表明POMS患者受到长期残疾保护.

研究的目的:

  • 为了比较POMS中独立于复发活动的进展率 (PIRA) 和复发相关恶化的发生率 (RAW),与成人发病的MS (AOMS) 和晚发病的MS (LOMS) 相比.
  • 在不同MS发病组中识别与PIRA和RAW相关的因素.

主要方法:

  • 一项使用意大利多发性硬化病登记册 (2000年6月至2021年9月) 预期获取数据的队列研究.
  • 分析了来自16130名多发性硬化患者的纵向数据,比较了POMS,AOMS和LOMS.
  • 评估临床和MRI特征,疾病修饰疗法 (DMT) 暴露,以及第一次DMT的时间.

主要成果:

  • 与AOMS和LOMS相比,POMS患者表现出较少的残疾,更活跃的疾病和更长时间的DMT暴露.
  • 与AOMS (44.3%) 和LOMS (56.8%) 相比,POMS (40.4%) 的PIRA累积发病率较低.
  • 发病时年龄较大,疾病持续时间较长,DMT暴露时间较短与PIRA风险较高有关. 延迟开始使用DMT会增加PIRA和RAW的风险.

结论:

  • 虽然POMS患者在十年内不太可能表现出PIRA,但儿科发病并不能完全防止疾病的进展.
  • 这些发现强调了所有多发性硬化症患者早期开始使用DMT的重要性,以减轻PIRA和RAW的风险.
  • 开始使用DMT与PIRA和RAW的发病率降低有关,不论发病时的年龄如何.